Promising results for CML
Tuesday, 09 December, 2008
Melbourne’s ChemGenex has released interim data of its Phase II/III trial of a compound for chronic myeloid leukaemia.
The trial involves 44 patients with the T315I mutation who have not responded to Novartis’ Glivec, or imatinib.
ChemGenex’s compound, omacetaxine mepesuccinate, showed good responses in chronic phase patients and was well tolerated, the company said.
The trial results were reported by trial investigator Jorge Cortes of the MD Anderson Cancer Center at a haematology conference in the US.
ChemGenex CEO Dr Greg Collier said the data would probably form part of the clinical section of the company’s new drug application to the US FDA next year.
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
